CAROLINE GIUSTRA: Open Payments
NPI 1588223226 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,564 in 125 payments from 21 companies in 2025. Trend: 2023 $2,958 · 2024 $4,041 · 2025 $4,564
Food & beverage: $3,369Consulting: $1,140Education: $55
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 16 | $1,643 |
| ABBVIE INC. | 23 | $563 |
| Regeneron Healthcare Solutions, Inc. | 12 | $449 |
| Galderma Laboratories, L.P. | 13 | $320 |
| Amgen Inc. | 12 | $263 |
| Lilly USA, LLC | 2 | $154 |
| Incyte Corporation | 7 | $149 |
| Organon LLC | 3 | $146 |
| Arcutis Biotherapeutics, Inc. | 8 | $139 |
| Novartis Pharmaceuticals Corporation | 6 | $128 |
Products named: Bimzelx, DUPIXENT, RINVOQ, SKYRIZI, NEMLUVIO, OTEZLA, OPZELURA, VTAMA.
Industry payments across GA — which companies pay providers there.
